felimazole vet. 5 mg tabletti, päällystetty
dechra regulatory b.v. - thiamazole - tabletti, päällystetty - 5 mg - tiamatsoli
felimazole vet. 2.5 mg tabletti, päällystetty
dechra regulatory b.v. - thiamazole - tabletti, päällystetty - 2.5 mg - tiamatsoli
felimazole vet. 1.25 mg tabletti, päällystetty
dechra regulatory b.v. - thiamazole - tabletti, päällystetty - 1.25 mg - tiamatsoli
apelka vet 5 mg/ml oraaliliuos
norbrook laboratories (ireland) limited - thiamazole - oraaliliuos - 5 mg/ml - tiamatsoli
baycoxine vet 50 mg/ml oraalisuspensio
bayer animal health gmbh - toltrazuril - oraalisuspensio - 50 mg/ml - toltratsuriili
chanox vet 50 mg/ml oraalisuspensio
chanelle pharmaceuticals manufacturing limited - toltrazuril - oraalisuspensio - 50 mg/ml - toltratsuriili
thiamacare vet 10 mg/ml oraaliliuos
ecuphar nv - thiamazole - oraaliliuos - 10 mg/ml - tiamatsoli
felithyrol vet 5 mg/ml oraaliliuos
cp-pharma handelsgesellschaft mbh - thiamazole - oraaliliuos - 5 mg/ml - tiamatsoli
atriance
sandoz pharmaceuticals d.d. - nelarabiini - prekursori t-solulymfoblastinen leukemia-lymfooma - antineoplastiset aineet - nelarabiini on tarkoitettu niiden potilaiden hoitoon akuutin t-lymfoblastisen leukemian (t-all) ja t-lymfoblastisen lymfooman (t-lbl), joiden tauti ei ole reagoinut tai on uusiutunut hoidon jälkeen vähintään kaksi solunsalpaajahoito. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.
revolade
novartis europharm limited - eltrombopag - purpura, trombosytopeeninen, idiopaattinen - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ja 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ja 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.